Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

Inogen, Inc. INGN is well-poised for growth in the coming quarters, backed by high prospects in the portable oxygen concentrator (POC) space. The optimism, led by a diversified and expanding product portfolio, strong momentum in international markets and a growing total addressable market, seems justified. However, U.S. revenue pressure from channel shifts and reimbursement conditions remains a key risk.

This Zacks Rank #3 (Hold) company’s shares have declined 16.7% in the year-to-date period compared with the industry’s 7.2% fall. However, the S&P 500 has risen 11.2% during the same timeframe.

The renowned provider of POCs has a market capitalization of $150.7 million. The company projects 13.9% earnings growth for 2026 and anticipates continued business improvements going forward. Inogen’s P/S ratio of 0.4 compared with the industry’s 2.7 makes its valuation attractive.

Image Source: Zacks Investment Research

Let’s delve deeper.

Factors Driving INGN’s Prospects

Strong POC Demand and Growing B2B Momentum: Portable oxygen concentrators (POCs) remain Inogen’s core growth engine, with unit volumes increasing more than 12% year over year in the second quarter of 2026. Management said the company continues to outpace market growth as it gains traction with more U.S. distributors. U.S. B2B revenues grew at a mid-single-digit rate, while the number of customers moving through the B2B channel increased sequentially from the first quarter. Inogen is also strengthening its value proposition to home medical equipment (HME) providers through an eight-year useful life, compared with the five-year industry standard, along with serviceability, availability and growing real-world outcomes data. This supports the company's strategy of shifting toward HME-led POC adoption and building a more sustainable U.S. growth channel.

New Products Expand Inogen’s Addressable Market: Inogen is diversifying beyond its traditional POC portfolio through Voxi stationary oxygen concentrators and Aurora CPAP masks. The two products contributed more than 100 basis points to second-quarter growth, while Voxi has surpassed 5,000 units shipped. Management estimates the U.S. stationary oxygen concentrator market at approximately $300 million and the CPAP mask market at roughly $2.2 billion, providing significant opportunities to expand within existing HME relationships. Aurora’s customer count more than doubled sequentially, while both products continue to receive positive feedback from patients and healthcare providers. These launches could become larger contributors as account penetration and adoption increase during the second half of 2026.

International Expansion Remains a Consistent Growth Engine: International revenues increased 15% year over year to $41.3 million in the second quarter, marking the 10th consecutive quarter of double-digit international growth. Inogen continues to deepen distributor relationships while expanding across Eastern Europe and Latin America, with the Rove 6 POC recently launched in Canada following its Brazil launch in the prior quarter. Management views these geographic expansions as part of a repeatable strategy to enter new markets and improve access to portable oxygen therapy. Although the timing of certain distributor purchases may affect the second half of 2026, the company expects international expansion to remain a long-term source of growth.

INGN: Key Risks to Watch

U.S. Channel Mix Continues to Pressure Direct and Rental Revenues: Inogen's U.S. business remains exposed to a structural shift toward HMEs prescribing POCs when patients first enter long-term oxygen therapy. While this benefits the B2B channel, it reduces the traditional funnel for Inogen's direct-to-consumer (DTC) and rental businesses. U.S. sales declined 2% year over year in the second quarter, while rental revenues fell 12%. Management expects continued DTC declines in the second half, with B2B gains only partially offsetting the pressure. Although the company sees opportunities to stabilize DTC and improve rental performance, the faster-than-anticipated channel shift remains a significant near-term constraint on U.S. growth.

International Distributor Inventory Timing Could Create Volatility: Despite sustained international growth, Inogen expects certain distributors to manage inventory during the second half of 2026. Management attributed the anticipated slowdown to factors including delayed tenders and distributor consolidation, describing the impact as transitory. However, the company incorporated the timing of these purchases into its revised outlook, with third-quarter revenues expected to be roughly in line with the prior-year period. Because international sales have been an important contributor to overall growth, changes in distributor purchasing patterns could create quarterly revenue volatility even if underlying demand remains healthy.

Reimbursement and Clinical Execution Risk for Simeox: Inogen’s Simeox airway-clearance technology represents a potentially significant growth opportunity, but its commercial potential depends on clinical evidence and reimbursement progress. Management estimates a U.S. total addressable market of approximately $500 million in non-cystic fibrosis bronchiectasis, but access to this market is tied to CMS reimbursement. The IMPACTS-200 trial is progressing as planned, while Inogen expects to conduct a second trial to build a stronger evidence package for CMS and payers. Management noted that the company effectively has “one shot on goal” with the reimbursement process, making successful clinical outcomes and coverage decisions critical to Simeox’s future contribution. Delays or unfavorable outcomes could push out the product’s commercial opportunity and limit the pace of portfolio diversification.

Inogen, Inc Price

Inogen, Inc price | Inogen, Inc Quote

INGN’s Estimate Trend

Inogen has been witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for its loss per share has contracted by 3 cents to 74 cents.

The Zacks Consensus Estimate for 2026 revenues is pegged at $356.7 million, suggesting a 2.3% improvement from the year-ago reported number.

Key Picks

Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research